Mellaril-s (thioridazine) is a small molecule pharmaceutical. Thioridazine was first approved as Mellaril-s on 1982-01-01. It is used to treat psychotic disorders and schizophrenia in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2C and 5-hydroxytryptamine receptor 2A. In addition, it is known to target D(1B) dopamine receptor, G protein-activated inward rectifier potassium channel 2, 5-hydroxytryptamine receptor 6, histamine H1 receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 7, D(1A) dopamine receptor, and mucosa-associated lymphoid tissue lymphoma translocation protein 1.
|Indication||psychotic disorders, schizophrenia|
|Drug Class||Typical antipsychotic|